FORVIXUS Trademark

Trademark Overview


On Tuesday, November 19, 2019, a trademark application was filed for FORVIXUS with the United States Patent and Trademark Office. The USPTO has given the FORVIXUS trademark a serial number of 88698665. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 3, 2022. This trademark is owned by Eli Lilly and Company. The FORVIXUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
forvixus

General Information


Serial Number88698665
Word MarkFORVIXUS
Filing DateTuesday, November 19, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 3, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 7, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain
Pseudo MarkFOR VIXUS

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 26, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, January 3, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 3, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, May 19, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 17, 2021EXTENSION 2 GRANTED
Monday, May 17, 2021EXTENSION 2 FILED
Monday, May 17, 2021TEAS EXTENSION RECEIVED
Tuesday, December 1, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 30, 2020EXTENSION 1 GRANTED
Monday, November 16, 2020EXTENSION 1 FILED
Monday, November 30, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, November 16, 2020TEAS EXTENSION RECEIVED
Tuesday, June 2, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 7, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 7, 2020PUBLISHED FOR OPPOSITION
Wednesday, March 18, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, March 2, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Sunday, February 23, 2020ASSIGNED TO EXAMINER
Tuesday, November 26, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, November 22, 2019NEW APPLICATION ENTERED IN TRAM